B. C. Astor, P. Muntner, A. Levin, J. A. Eustace and J. Coresh, “Association of Kidney Function With Anemia The Third National Health and Nutrition Examination Survey (1988-1994),” Archives of Internal Medicine, 2002, Vol. 162, No. 12, pp. 1401-1408.doi10.1001/archinte.162.12.1401 - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

B. C. Astor, P. Muntner, A. Levin, J. A. Eustace and J. Coresh, “Association of Kidney Function With Anemia: The Third National Health and Nutrition Examination Survey (1988-1994),” Archives of Internal Medicine, 2002, Vol. 162, No. 12, pp. 1401-1408. doi:10.1001/archinte.162.12.1401

has been cited by the following article:

TITLE: Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure

AUTHORS: Iqbal Masood, Geoffrey Teehan

KEYWORDS: Anemia; Chronic Kidney Disease (CKD); End Stage Renal Disease (ESRD); Erythropoiesis Stimulating Agents (ESA); Epoetin Alfa (EPO)

JOURNAL NAME: Open Journal of Nephrology, Vol.2 No.4, December 18, 2012

ABSTRACT: Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance (i.e. inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.